Board of Directors

Martyn D. Greenacre has served on the Board since February 2000 and has served as Chairman of the Board since May 2017. From June 1993 to July 2000, he was a director of Creative BioMolecules, Inc., a predecessor life science company of Curis. Mr. Greenacre served as Chairman of Life Mist L.L.C., a privately-held company in the field of fire suppression, from September 2001 to December 2016. From June 1997 to June 2001, he was Chief Executive Officer of Delsys Pharmaceutical Corporation, a drug formulation company. From 1993 to 1997, Mr. Greenacre was President and Chief Executive Officer of Zynaxis, Inc., a biopharmaceutical company. Prior to Zynaxis, Inc., he served in various senior management positions at SmithKline Beecham Limited, a pharmaceuticals company, from 1973 through 1992, including as Chairman of European Operations and was appointed to its Board of Directors. Previously, he served as a director of Acusphere, Inc., Cephalon, Inc., Formula Pharmaceuticals, Neostem, Inc. (now Caladrius, Inc.) and Orchestra Therapeutics, Inc., and as a director and Chairman of BMP Sunstone Corporation. Mr. Greenacre received a B.A. from Harvard College and an M.B.A. from Harvard Business School.

Committee:

Audit
Nominating and Governance